Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5800798 | 0.86 | GAA (0.33) | GAANPSR1 | |
| SCHEMBL29358961 | 0.73 | GAA (0.60) | GAANPSR1 | |
| SCHEMBL323313 | 0.73 | GAA (0.60) | GAANPSR1 | |
| SCHEMBL852319 | 0.70 | ALOX5 (0.46) | — | |
| SCHEMBL2033180 | 0.69 | — | — | |
| SCHEMBL3354708 | 0.68 | MAOA (0.33) | — | |
| SCHEMBL11194900 | 0.68 | GAA (0.33) | GAANPSR1 | |
| SCHEMBL7275367 | 0.68 | MAPT (0.35) | GAANPSR1 | |
| Biphenyl SCHEMBL28612860 | 0.68 | GAA (0.53) | GAANPSR1 | |
| SCHEMBL9642249 | 0.68 | FABP6 (0.38) | GAANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040101523-A1 | Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension | G.D. SEARLE & CO. | 2004-05-27 | — | — | US | claimed |
| WO-1992001667-A1 | RENAL-SELECTIVE PRODRUGS FOR CONTROL OF RENAL SYMPATHETIC NERVE ACTIVITY IN THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1992-02-06 | — | — | WO | claimed |
| US-11603373-B2 | TDO2 and IDO1 inhibitors | GENENTECH, INC. (US) | 2023-03-14 | — | — | US | disclosed |
| US-20200123163-A1 | TDO2 and IDO1 Inhibitors | GENENTECH, INC. | 2020-04-23 | — | — | US | disclosed |
| US-20030220521-A1 | Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension | G.D. SEARLE & CO. | 2003-11-27 | — | — | US | disclosed |
| EP-0484437-A4 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | SEARLE & CO (US) | 1994-06-01 | — | — | EP | disclosed |
| EP-0484437-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. Searle & Co. (US) | 1992-05-13 | — | — | EP | disclosed |
| WO-1992001667-A1 | RENAL-SELECTIVE PRODRUGS FOR CONTROL OF RENAL SYMPATHETIC NERVE ACTIVITY IN THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1992-02-06 | — | — | WO | disclosed |
| WO-1991001724-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1991-02-21 | — | — | WO | disclosed |
| US-4271187-A | Substituted phenyl alanine antihypertensive agents | MERCK & CO., INC. (US) | 1981-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11603373-B2 | TDO2 and IDO1 inhibitors | IDO1, TDO2, IDO2 | GAA 2380/4885NPSR1 2290/4885 |
| US-20030220521-A1 | Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension | GLS, APEH, GGH | GAA 171/4885NPSR1 622/4885 |
| US-20200123163-A1 | TDO2 and IDO1 Inhibitors | IDO1, TDO2, IDO2 | GAA 2380/4885NPSR1 2290/4885 |
| US-20040101523-A1 | Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension | GLS, DBH, APEH | GAA 111/4885NPSR1 537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.